Journals / Retina-Vitreus / 2015 / Cilt: 23 - Sayı: 0

Intravitreal Hemorrhage Following İntravitreal Ranibizumab İnjection in a Patient Using Warfarin

Warfarin Kullanan Bir Hastada İntravitreal Ranibizumab Enjeksiyonu Sonrası Gelişen Vitreus İçi Hemoraji

Pages
255–258
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this case we reported intravitreal hemorrhage following intravitreal injection of ranibizumab for exudative age-related macular degeneration in a 78 -year-old male using oral anticoagulant (Warfarin)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Intravitreal injection of anti vascular endothelial growth factors (anti-VEGF) are commonly used to treat various retinal disorders.
📊
Key Findings & Data:Since elderly people comprise the majority of patients, systemic diseases may accompany these retinal disorders.
💡
Conclusion & Impact:In this case we reported intravitreal hemorrhage following intravitreal injection of ranibizumab for exudative age-related macular degeneration in a 78 -year-old male using oral anticoagulant (Warfarin)
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Intravitreal injection of anti vascular endothelial growth factors (anti-VEGF) are commonly used to treat various retinal disorders. Since elderly people comprise the majority of patients, systemic diseases may accompany these retinal disorders. Furthermore oral anticoagulant usage is very common in these patients. In this case we reported intravitreal hemorrhage following intravitreal injection of ranibizumab for exudative age-related macular degeneration in a 78 -year-old male using oral anticoagulant (Warfarin)

Özet

Anti-vasküler endotelyal büyüme faktörlerinin (anti-VEGF) intravitreal enjeksiyonu çeşitli retinal hastalıkların medikal tedavisinde yaygın olarak kullanılmaktadır. Hastaların büyük bölümünü orta ve ileri yaş grubu oluşturduğu için göz bulgularına çeşitli sistemik hastalıklar eşlik edebilmektedir. Oral antikoagülan kullanımı da bu hasta grubunda yaygındır. Bu vaka sunumunda oral antikoagülan (warfarin) kullanan 78 yaşında bir erkek hastada eksudatif yaşa bağlı maküla degenerasyonu nedeniyle yapılan intravitreal ranibizumab enjeksiyonu sonrasında meydana gelen vitreus içi hemoraji tartışıldı

🔖

Cite This Article

YAZGAN, S., KALDIRIM, H., AYAR, O. (2015). Intravitreal Hemorrhage Following İntravitreal Ranibizumab İnjection in a Patient Using Warfarin. Retina-Vitreus, Cilt: 23 - Sayı: 0, 255–258. https://ajindex.com/articles/308033

References (7)

  1. Yuan A, Ahmad BU, Xu D, et al. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to reti- nal vein occlusion. Int J Ophthalmol 2014;7:86-91.
  2. Kim JH, Chang YS, Kim JW, et al. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovasculariza- tion. Ophthalmology 2014;121:926-35. Bloch SB. Implementation studies of ranibizumab for neovascular age- related macular degeneration. Acta Ophthalmol 2013;91-7:1-22. Arevalo JF. Diabetic macular edema: Current management 2013. World J Diabetes 2013;15:231-3. Schulman S. Oral anticoagulation. Williams Hematology, 2001,
  3. Part X, Chapter 132;1777-92.
  4. Alay M, Demir C, Atmaca M, ve ark. Oral antikoagulan tedavi seyrinde kanama komplikasyonu ile gelen hastaların değerlendirilmesi. Van Tıp Derg 2011:18:9-14.
  5. Landefeld CS, Beyth RJ. Anticoagulantrelated bleeding: clinical epidemi- ology, prediction, and prevention. Am J Med 1993;95:315-28.
  6. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anti- coagulant treatment: an inception-cohort,prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Thera- py. Lancet 1996;348:423-8.
  7. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antiyhrombotic therapy. BMJ 2002;325:828-31. Mason JO 3rd, Frederick PA, Neimkin MG, et al. Incidence of hemor- rhagic complications after intravitreal bevacizumab (avastin) or ranibi- zumab (lucentis) injections on systemically anticoagulated patients. Ret- ina 2010;30:1386-9.